Tangled leads: Cardiac study retraction reveals a company’s stopped trials, and lots of questions

A retraction in an obscure journal. An equally obscure retraction notice. An Israeli company with no web presence. Conflicts of interest involving authors and editors.

That’s what we’ve uncovered so far after noticing the other day that the American Journal of the Medical Sciences (AJMS) had retracted a May 2010 article by a group of Israeli heart doctors led by Arthur Shiyovich, of Barzilai Medical Center in Ashkelon.

The paper described promising results in a study of a new test for diagnosing coronary artery disease at the bedside by measuring aspects of a patient’s pulse at the fingertip.

As AJMS editor David Ploth told us, the approach had seemed “kind of innovative” to him, so he’d accepted the manuscript: “It seemed like it might have some applicability.”

Ploth was therefore surprised sometime later to receive a letter from the authors requesting that the journal retract their paper. According to the journal: Continue reading Tangled leads: Cardiac study retraction reveals a company’s stopped trials, and lots of questions

Exclusive: Researcher found guilty of misconduct at UCL had been dismissed from Cambridge for data fabrication

Here at Retraction Watch, we’ve been following the case of Jatinder Ahluwalia with interest. You may recall that an investigation by University College London (UCL) found “beyond reasonable doubt” that Ahluwalia had renumbered files to deceive a co-author. UCL was also “highly confident” that Ahluwalia had messed with his solutions to make his results look better, and sabotaged his colleagues’ work. The report of that investigation was part of a Nature retraction notice.

We’ve now learned that UCL was not the first scene of misconduct by Ahluwalia. Yesterday, we obtained letters by University of Cambridge faculty and administrators describing repeated — and in the words of of one professor, amateurish — data fabrication by Ahluwalia that led to his dismissal from the university’s graduate program.

In a letter dated November 10, 1997, Martin Brand, then Ahluwalia’s PhD advisor, wrote: Continue reading Exclusive: Researcher found guilty of misconduct at UCL had been dismissed from Cambridge for data fabrication

“Biologist realizes he’s been studying Cadbury egg”: Mislabeled bottle leads to Phys Rev B retraction

The quote in the title of this post is a potential Onion headline that didn’t make it into print. It was part of an episode of This American Life that aired last week, and it seemed apropos, even though the subject here is superconductors rather than biology.

After all, we’ve written about a retraction that resulted from ordering the wrong mice. Today, we bring you the tale of a retraction caused by a mislabeled bottle. According to a retraction notice that appeared online last month in Physical Review B: Continue reading “Biologist realizes he’s been studying Cadbury egg”: Mislabeled bottle leads to Phys Rev B retraction

Unglaublich! Boldt investigation may lead to more than 90 retractions

Ludwigshafen Hospital, via Wikimedia http://commons.wikimedia.org/wiki/File:Klinikum_Ludwigshafen_Nordseite.jpg

Self-plagiarism alert: A very similar version of this post is being published online in Anesthesiology News, where one of us (AM) is managing editor.

Unglaublich is the German word for unbelievable, and it’s an apt description for the latest development in the case of Joachim Boldt.

Boldt, a prominent German anesthesiologist, has been at the center of a research and publishing investigation since last October, when the journal Anesthesia & Analgesia retracted a 2009 article of his over concerns of data manipulation. This morning, the German medical board overseeing the case, the Landesärztekammer Rheinland-Pfalz (LÄK-RLP),  released its findings — and they are truly stunning.

According to LAK, somewhere in the neighborhood of 90 of Boldt’s published articles might require retraction because the investigator failed to obtain approval from an institutional review board to conduct the research.

We don’t read German. But, fortunately, the LÄK-RLP announcement was accompanied by a joint letter posted to the websites of 11 major anesthesia journals. We do read English, and here’s what that letter says: Continue reading Unglaublich! Boldt investigation may lead to more than 90 retractions

Three more Bulfone-Paus retraction notices out, in Journal of Immunology

Silvia Bulfone-Paus

The retraction notices for papers by Silvia Bulfone-Paus continue to appear. Yesterday, the Journal of Immunology posted notices for these three previously accepted retractions by the researcher, work at whose Borstel Centre lab is under investigation for misconduct.

We wrote what? Breast cancer paper falls to rogue author

Something was fishy at China Normal University. According to the journal Anti-Cancer Drugs, a 2010 paper by researchers at the Beijing school — “3,30′-Diindolylmethane negatively regulates Cdc25A and induces a G2/M arrest by modulation of microRNA21 in human breast cancer cells” — turned out to have suffered from an unfortunate anomaly. According to the retraction notice: Continue reading We wrote what? Breast cancer paper falls to rogue author

In retraction notice, Bulfone-Paus “declares” data and conclusions confirmed; journals accept six more retractions

Silvia Bulfone-Paus

There was more news today about papers co-authored by Silvia Bulfone-Paus, whose lab at Research Centre Borstel has been under investigation for scientific misconduct.

The EMBO Journal, which we reported last month had accepted the retraction of a 2005 Bulfone-Paus paper that has been cited 37 times, published the retraction notice for the study today:

Eight of the authors (ZO, LT, UM, PB, CB, DA, RP and SB-P) wish to retract this paper, following an independent formal investigation initiated by the Research Center Borstel into scientific misconduct (see http://www.fz-borstel.de/cms/index.php?id=1). The investigation concluded that multiple figures contained PCR and western blot duplications and possible other manipulations (Figures 2A, 3A, 4A, 5, 7A and 7C, Supplementary Figures S1A, S2A and S2B, unconfirmed: Figure 1C). The above signed declare that Vadim Budagian and Elena Bulanova conducted these experiments and generated the figures. The authors declare that key experiments presented in the majority of these figures were recently reproduced and that the results confirmed the experimental data and the conclusions drawn from them. However, due to these unacceptable irregularities, the listed authors retract this paper in its entirety and regret any adverse consequences that may have resulted from its publication. Vadim Budagian and Elena Bulanova declined to sign the retraction.

As retraction notices go, this is better than average, we must say. It’s certainly better than the many opaque notices we’ve seen. But there’s a line in there that Karin Wiebauer and David Hardman, both of whom brought the notice to our attention, found curious: Continue reading In retraction notice, Bulfone-Paus “declares” data and conclusions confirmed; journals accept six more retractions

No Potti retractions on the horizon from JAMA, NEJM

With the third retraction of a paper by Anil Potti this weekend, plus details of various investigations dribbling out, we decided to check in with the world’s two leading medical journals about whether they planned to retract the papers of Potti’s they’d published.

JAMA published two papers by Potti and colleagues: One, “Gene Expression Signatures, Clinicopathological Features, and Individualized Therapy in Breast Cancer,” appeared in 2008. It has been cited 51 times, according to Thomson Scientific’s Web of Knowledge, and was the subject of two letters. In one, a correspondent expressed concerns about the lack of information in the study about Continue reading No Potti retractions on the horizon from JAMA, NEJM

Lancet Oncology retracts previously questioned Anil Potti paper

courtesy Duke

Early in December, as the house of cards that is Anil Potti‘s publication record started to really collapse, we called attention to a paper in The Lancet Oncology that had already been the subject of a correction and Expression of Concern in July of last year. Today, the journal officially retracted the paper, “Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.” The paper was cited more than 100 times, according to Google Scholar.

The retraction notice: Continue reading Lancet Oncology retracts previously questioned Anil Potti paper

Georgia (well, the Medical College there, anyway) on our minds for a mysterious retraction

We’re watching a case which appears to involve more than meets the eye.

Molecular Endocrinology has retracted a 2010 study by researchers at the Medical College of Georgia. According to the Spartan retraction notice (we added a link): Continue reading Georgia (well, the Medical College there, anyway) on our minds for a mysterious retraction